Operating Income: The income after operating expenses.
Sinovac Biotech, Ltd. (SVA) had Operating Income of $-490.13M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$386.01M |
|
$-59.68M |
|
$124.03M |
|
$261.98M |
|
$876.14M |
|
|
Operating Income |
$-490.13M |
$228.03M |
|
$-262.10M |
|
$-262.10M |
|
$-198.84M |
|
$-198.84M |
|
$-198.84M |
|
$-198.84M |
|
$-490.13M |
|
$-391.35M |
|
71.86M |
|
71.86M |
|
$-0.83 |
|
$-0.83 |
|
| Balance Sheet Financials | |
$7.06B |
|
$706.06M |
|
$1.48B |
|
$8.54B |
|
$1.54B |
|
$265.48M |
|
$605.11M |
|
$2.15B |
|
$6.40B |
|
$6.31B |
|
$6.40B |
|
71.86M |
|
| Cash Flow Statement Financials | |
$-512.18M |
|
$4.39B |
|
$-3.43B |
|
$602.22M |
|
$1.16B |
|
$554.21M |
|
-- |
|
$-3.53B |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.59 |
|
-- |
|
-- |
|
0.04 |
|
0.08 |
|
67.87% |
|
-126.97% |
|
-126.97% |
|
-101.38% |
|
-67.90% |
|
-15.46% |
|
$-560.69M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
1.32 |
|
1.23 |
|
296.04 |
|
-3.11% |
|
-3.15% |
|
-2.33% |
|
-2.98% |
|
$89.01 |
|
$-7.80 |
|
$-7.13 |
|